A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial

Blauvelt, A. ; Leonardi, C. ; Elewski, B. ; Crowley, J.J. ; Guenther, L.C. ; Gooderham, M. ; Langley, R.G. ; Vender, R. ; Pinter, A. ; Griffiths, C.E.M. ; Tada, Y. ; Elmaraghy, H. ; Lima, R.G. ; Gallo, G. ; Renda, L. ; Burge, R. ; Park, S.Y. ; Zhu, B. ; Papp, K.

British journal of dermatology (1951), 2021-06, Vol.184 (6), p.1047-1058 [Peer Reviewed Journal]

Oxford: Oxford University Press

Full text available